Lipids in Pulmonary Drug Delivery

Md Faiyazuddin stands out as a leading figure in pharmacy education and research, distinguished by his comprehensive background and contributions to the field. Renowned for his prolific contributions to the field, Dr. Faiyazuddin is an avid researcher, delving into various facets of formulation science. As the founder Dean R&D at Al – Karim University and a Professor of Pharmaceutics, he is at the forefront of health and drug delivery research. With 18 years of experience, Dr. Faiyazuddin is currently the founder Dean R&D and Professor of Pharmaceutics at Al – Karim University. Previously, he served as Dean and Professor at The R. C. University, Principal at Bihar College of Pharmacy, and held various academic and research positions at the University of Hail and Integral University. He is advising Nano Drug Delivery® USA (A product development partnership company) for product development, optimization, and scale-up of Nanopharmaceutical. Holding a PhD in Pharmaceutics from Jamia Hamdard, New Delhi, India, Dr. Faiyazuddin specializes in pharmaceutical nanotechnology and earned an executive strategic leadership management degree at the Jacobs-Abbey Global Institute for Leadership Studies, Woodbridge, Virginia, USA. He has extensive research experience in pharmaceutical nanotechnology, advanced drug delivery, marine bioactive, and recently pharmaceutical AI and probiotics medicines. He is a visiting scientist and adjunct professor of reputed universities at the national as well as international level sharing outstanding ideas and cutting-edge technologies with laureates in health and the pharmaceutical sectors. He serves as an editorial board member and reviewer for several high-impact international scientific journals published by Lancet, Cell press, Elsevier, ACS, Springer Nature, RSC, Taylor and Francis, Cambridge, and John Wiley. His scholarly contributions are substantial, with over 150 peer-reviewed articles published in top-tier journals such as ACS, Elsevier, and Wiley, alongside 9 patents, 12 books, and 62 book chapters. He has been recognized with 8 awards, including the DST Young Scientist Award (2012), Dr. P.D. Sethi Award (2010), and the Global Peace Building Award (2023). Additionally, he holds 7 fellowships, has chaired 15 editorial boards and conferences, and delivered over 50 invited conference presentations.He has secured and effectively managed research grants from several prominent research and development agencies. These include SERB-DST, as well as international bodies such as DSR-UoH-KSA, NJ-KSA, KAUST, UiTM Malaysia, and SickKids Hospital in Canada. The total value of these grants exceeds Rs. 1.12 Million INR, underscoring his ability to attract and successfully execute high-profile research projects. His expertise in attracting and executing high-profile research projects is well demonstrated. Additionally, he has developed and implemented innovative educational tools and programs that address critical needs in diverse and underserved communities, advancing both scientific research and educational access.Hasan Ali is presently working as an Associate Professor in the Department of Pharmacy at Meerut Institute of Technology in Meerut, India. With a wealth of experience in the field, he specializes in pharmacy and pharmaceutical nanotechnology. His expertise spans various aspects of pharmaceutical sciences, with a focus on the development and application of nanotechnology in drug delivery and therapeutic innovations. His work integrates cutting-edge research with practical applications, contributing significantly to advancements in the pharmaceutical industry.Md Akbar holds a doctoral degree in Pharmaceutical Medicine from the School of Pharmaceutical Education and Research at Jamia Hamdard, New Delhi, India, and a postgraduate diploma in Drug Regulatory Affairs. With over a decade of diverse experience in the pharmaceutical industry and academia, Dr. Akbar has worked in Pharmaceutical Regulatory Affairs, Medical Writing, and Medical Communication at several esteemed pharmaceutical companies. Additionally, he has served as a faculty member at various universities. He is currently an Assistant Professor at the School of Pharmacy, Al – Karim University, Katihar, India.Babar Iqbal is currently working as a manager in the Formulation and Development department of Unicure India Ltd., Noida. Dr. Iqbal received his M. Pharm. in pharmaceutics from Faculty of Pharmacy, Jamia Hamdard, and doctorate in pharmaceutics from the Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, India. During his M. Pharm. Degree, he availed of the merit based AICTE sponsored scholarship, and in his doctorate, he received a fellowship by Government of India. He brings extensive experience in formulation development and pharmaceutical nanotechnology to his role. His expertise encompasses various aspects of creating and refining pharmaceutical formulations, with a particular focus on integrating nanotechnology to enhance drug efficacy and delivery systems. With more than 10 years of industry and research experience, he has published several research and review articles in the peer-reviewed journals of international repute, and book chapters.

• Lipid NanotechnologyCurrent Scenario and Challenges of Lipid-Based Nanomedicines for Pulmonary Drug DeliveryEffect of Environment of the Respiratory Tract on Nanomedicine Drug DeliveryAerodynamics and Deposition of Lipid-Based Nanocarriers in LungsLiposome as a Versatile Carrier for Pulmonary Drug DeliveryAdvancements in Nano-Structured Lipid Carrier (NLCs) as Drug Delivery Vehicle in LungsSolid Lipid Nanoparticles: A Potential Drug Carrier in Pulmonary SystemInsights and Applications of Nanoemulsions as a Drug Carrier in LungsLipid-Based Drug Delivery for Lung CancerExploring the State-of-Art of Lipid Nanomedicines for Obstructive Pulmonary DiseasesLipid-Based Drug Delivery for Pulmonary Microbial InfectionsLipid-Based Drug Delivery for Systemic Effect Through Pulmonary Route of AdministrationBiofate of Lipid-Based Nanomedicine After Pulmonary AdministrationSurface Modification of Lipid-Based Drug Delivery for LungsEvaluation of Lipid-Based Formulation for Pulmonary DeliveryPhysico-Chemical Stability of Lipid-Based Nanocarriers in Aerosol FormulationTranslation of Lipid-Based Formulation for Pulmonary Drug Delivery System: Clinical StatusRegulatory Aspects of Lipid-Based Nanomedicine for Pulmonary ApplicationsLipid-Based Vaccines Against Viruses Including COVID-19Lipid-Based Nanocarriers in the Management of Cystic Fibrosis: A Pulmonary ComplicationPulmonary Drug Delivery of Lipid-Based Formulations via NebulizersLipid-Based Peptide and Gene Delivery to Lungs